| Title |
Measuring the end-of-life premium in cancer using individual ex ante willingness to pay
|
|---|---|
| Published in |
HEPAC Health Economics in Prevention and Care, August 2017
|
| DOI | 10.1007/s10198-017-0922-6 |
| Pubmed ID | |
| Authors |
S. Olofsson, U.-G. Gerdtham, L. Hultkrantz, U. Persson |
| Abstract |
For the assessment of value of new therapies in healthcare, Health Technology Assessment (HTA) agencies often review the cost per quality-adjusted life-year (QALY) gained. Some HTA agencies accept a higher cost per QALY gained when treatment is aimed at prolonging survival for patients with a short expected remaining lifetime, a so-called end-of-life (EoL) premium. The objective of this study is to elicit the existence and size of an EoL premium in cancer. Data was collected from 509 individuals in the Swedish general population 20-80 years old using a web-based questionnaire. Preferences were elicited using subjective risk estimation and the contingent valuation (CV) method. A split-sample design was applied to test for order bias. The mean value of a QALY was MSEK4.8 (€528,000), and there was an EoL premium of 4-10% at 6 months of expected remaining lifetime. Using subjective risk resulted in more robust and valid estimates of the value of a QALY. Order of scenarios did not have a significant impact on the WTP and the result showed scale sensitivity. Our result provides some support for the use of an EoL premium based on individual preferences when expected remaining lifetime is short and below 24 months. Furthermore, we find support for a value of a QALY that is above the current threshold of several HTA agencies. |
X Demographics
The data shown below were collected from the profiles of 3 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Canada | 1 | 33% |
| United Kingdom | 1 | 33% |
| Unknown | 1 | 33% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 3 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 41 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 41 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 10 | 24% |
| Student > Bachelor | 3 | 7% |
| Researcher | 3 | 7% |
| Student > Doctoral Student | 2 | 5% |
| Professor | 2 | 5% |
| Other | 7 | 17% |
| Unknown | 14 | 34% |
| Readers by discipline | Count | As % |
|---|---|---|
| Economics, Econometrics and Finance | 10 | 24% |
| Nursing and Health Professions | 4 | 10% |
| Pharmacology, Toxicology and Pharmaceutical Science | 3 | 7% |
| Medicine and Dentistry | 3 | 7% |
| Social Sciences | 3 | 7% |
| Other | 4 | 10% |
| Unknown | 14 | 34% |
Attention Score in Context
This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 19 September 2018.
All research outputs
#16,292,673
of 25,728,855 outputs
Outputs from HEPAC Health Economics in Prevention and Care
#868
of 1,315 outputs
Outputs of similar age
#187,166
of 328,654 outputs
Outputs of similar age from HEPAC Health Economics in Prevention and Care
#7
of 14 outputs
Altmetric has tracked 25,728,855 research outputs across all sources so far. This one is in the 34th percentile – i.e., 34% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,315 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.8. This one is in the 31st percentile – i.e., 31% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 328,654 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 39th percentile – i.e., 39% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 14 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 50% of its contemporaries.